PetMed Express, Inc. (NASDAQ:PETS) has earned a consensus recommendation of “Hold” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $42.80.
PETS has been the subject of a number of analyst reports. Zacks Investment Research raised PetMed Express from a “sell” rating to a “hold” rating and set a $50.00 price target for the company in a report on Friday, October 20th. BidaskClub raised PetMed Express from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 9th. Noble Financial reaffirmed a “hold” rating on shares of PetMed Express in a report on Friday, October 27th. Northcoast Research set a $58.00 price target on PetMed Express and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Finally, ValuEngine cut PetMed Express from a “buy” rating to a “hold” rating in a report on Monday, October 2nd.
In other PetMed Express news, Director Ronald J. Korn sold 1,000 shares of the stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $35.57, for a total transaction of $35,570.00. Following the completion of the transaction, the director now owns 73,833 shares of the company’s stock, valued at $2,626,239.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Menderes Akdag sold 30,000 shares of the stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $51.00, for a total value of $1,530,000.00. Following the transaction, the chief executive officer now directly owns 490,000 shares of the company’s stock, valued at approximately $24,990,000. The disclosure for this sale can be found here. Insiders have sold 51,000 shares of company stock valued at $2,453,170 in the last three months. Insiders own 4.00% of the company’s stock.
PetMed Express (PETS) opened at $53.24 on Friday. The firm has a market capitalization of $1,150.00, a PE ratio of 35.73, a P/E/G ratio of 3.00 and a beta of 1.12. PetMed Express has a fifty-two week low of $19.21 and a fifty-two week high of $53.90.
PetMed Express (NASDAQ:PETS) last released its quarterly earnings results on Monday, October 23rd. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.30 by $0.13. The company had revenue of $66.70 million during the quarter, compared to analysts’ expectations of $63.41 million. PetMed Express had a return on equity of 31.46% and a net margin of 11.58%. PetMed Express’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.24 EPS. research analysts predict that PetMed Express will post 1.68 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “PetMed Express, Inc. (PETS) Given Average Rating of “Hold” by Analysts” was posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/21/petmed-express-inc-pets-given-average-rating-of-hold-by-analysts.html.
About PetMed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.